Zirconium Zr 89 Crefmirlimab Berdoxam
Metastatic Solid Malignancies
ImaginAb, Inc.antibody_drug_conjugatePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Metastatic Solid Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ipilimumab National University Hospital, Singapore | Phase 1 | CC |
Selinexor National University Hospital, Singapore | Phase 1 | CC |
Regorafenib AHS Cancer Control Alberta | Phase 1 | CC |
Same molecule, other indications
Zirconium Zr 89 Crefmirlimab Berdoxam is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →